(VIANEWS) – Jiayin Group (JFIN), Knight Transportation (KNX), Magna International (MGA) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Jiayin Group (JFIN)
136.4% sales growth and 106.77% return on equity
Jiayin Group Inc. operates as an online individual finance platform that connects individual investors and individual borrowers in China. It operates a secure and open platform that facilitates transparent, secure, and fast connections between investors and borrowers. The company was founded in 2011 and is based in Shanghai, the People's Republic of China.
Earnings Per Share
As for profitability, Jiayin Group has a trailing twelve months EPS of $3.79.
PE Ratio
Jiayin Group has a trailing twelve months price to earnings ratio of 1.46. Meaning, the purchaser of the share is investing $1.46 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 106.77%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 64%, now sitting on 4.92B for the twelve trailing months.
Sales Growth
Jiayin Group’s sales growth is negative 3.5% for the ongoing quarter and 136.4% for the next.
2. Knight Transportation (KNX)
19.3% sales growth and 3.07% return on equity
Knight-Swift Transportation Holdings Inc., together with its subsidiaries, provides truckload transportation services in the United States and Mexico. The company operates through three segments: Trucking, Logistics, and Intermodal. Its trucking services include irregular route, dedicated, refrigerated, flatbed, expedited, dry van, drayage, and cross-border transportation of various products, goods, and materials. The company also provides logistics and intermodal services, such as brokerage, intermodal, and certain logistics; freight management; and non-trucking services. In addition, it offers various support services, including repair and maintenance shop services, warranty, insurance, and equipment leasing; and trailer parts manufacturing services, as well as engages in the driving academy activities. The company operates a total of 18,877 tractors, which comprises 16,432 company-owned tractors and 2,445 independent contractor tractors, as well as 58,315 trailers; and 643 tractors and 9,862 intermodal containers. It serves retail, food and beverage, consumer products, paper products, transportation and logistics, housing and building, automotive, and manufacturing industries. Knight-Swift Transportation Holdings Inc. was founded in 1989 and is headquartered in Phoenix, Arizona.
Earnings Per Share
As for profitability, Knight Transportation has a trailing twelve months EPS of $1.34.
PE Ratio
Knight Transportation has a trailing twelve months price to earnings ratio of 42.04. Meaning, the purchaser of the share is investing $42.04 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.07%.
3. Magna International (MGA)
14% sales growth and 10.89% return on equity
Magna International Inc. designs, engineers, and manufactures components, assemblies, systems, subsystems, and modules for original equipment manufacturers of vehicles and light trucks worldwide. It operates through four segments: Body Exteriors & Structures, Power & Vision, Seating Systems, and Complete Vehicles. The Body Exteriors & Structures segment provides body and chassis, exterior, and roof systems, as well as battery enclosures and engineering and testing services, including fascia and trims, front end modules, integration panels, liftgate modules, active aerodynamics, engineered glass, running boards, truck bed access products, breakthrough lightings, quarter windows, encapsulated glasses, and side doors. The Power & Vision segment offers ?electric drive systems and components, such as emotors, inverters, onboard chargers, gearboxes, and e-clutch; dedicated hybrid drives, dual and hybrid dual clutch, and manual transmissions; AWD/4WD products and rear drive modules; transmission, driveline components, and ICE; engineering services; advanced driver assistance systems sensors and, and electronic control units; interior and exterior mirrors, camera and driver monitoring systems and electronics, actuators, door handles, and overhead consoles; forward, rear, and auxiliary lighting products; latching, door modules, window, power closure, and hinges and wire forming systems; and modular and textile folding roofs, and hard and soft tops. The Seating Systems segment provides seat structures, mechanism and hardware solutions, and foam and trim products. The Complete Vehicles segment offers vehicle engineering and manufacturing services. The company also designs, engineers, and manufactures tooling products. Magna International Inc. was founded in 1957 and is headquartered in Aurora, Canada.
Earnings Per Share
As for profitability, Magna International has a trailing twelve months EPS of $4.23.
PE Ratio
Magna International has a trailing twelve months price to earnings ratio of 12.79. Meaning, the purchaser of the share is investing $12.79 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.89%.
Volume
Today’s last reported volume for Magna International is 119817 which is 90.06% below its average volume of 1205740.
Sales Growth
Magna International’s sales growth is 8.8% for the present quarter and 14% for the next.
4. CACI International (CACI)
9.4% sales growth and 11.67% return on equity
CACI International Inc, together with its subsidiaries, provides expertise and technology to enterprise and mission customers in support of national security missions and government modernization/transformation in the intelligence, defense, and federal civilian sectors. It operates in two segments, Domestic Operations and International Operations. The Domestic Operations segment provides information solutions and services to the U.S. federal government agencies and commercial enterprises in the areas, such as digital solutions, C4ISR, cyber and space, engineering services, enterprise IT, and mission support. The International Operations segment offers a range of IT services, proprietary data, and software products to commercial and government customers in the United Kingdom, continental Europe, and internationally. The company designs, develops, integrates, deploys, and sustains enterprise-wide IT systems in a variety of models; delivers cloud-powered solutions, performance-based service management, software-as-a service secure mobility, defensive cyber and network security, end-user services, and infrastructure services. It also delivers technology that includes developing and implementing digital solutions, and enterprise IT systems for enterprise customers; and technology for customers that includes developing and deploying multi-domain offerings for signals intelligence, resilient communications, free space optical communications, electronic warfare, and cyber operations. In addition, the company provides capabilities in areas, such as command and control, communications, intelligence collection and analysis, signals intelligence (SIGINT), electronic warfare, and cyber operations. Further, it offers investigation and litigation support services; and SIGINT and cyber products and solutions to the Intelligence Community and Department of Defense. The company was founded in 1962 and is headquartered in Reston, Virginia.
Earnings Per Share
As for profitability, CACI International has a trailing twelve months EPS of $16.47.
PE Ratio
CACI International has a trailing twelve months price to earnings ratio of 22.54. Meaning, the purchaser of the share is investing $22.54 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.67%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 11.2%, now sitting on 7.13B for the twelve trailing months.
Moving Average
CACI International’s worth is higher than its 50-day moving average of $338.60 and way above its 200-day moving average of $329.46.
Yearly Top and Bottom Value
CACI International’s stock is valued at $371.26 at 10:22 EST, below its 52-week high of $371.81 and way above its 52-week low of $275.79.
5. Vertex Pharmaceuticals (VRTX)
6.3% sales growth and 22.99% return on equity
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Earnings Per Share
As for profitability, Vertex Pharmaceuticals has a trailing twelve months EPS of $13.61.
PE Ratio
Vertex Pharmaceuticals has a trailing twelve months price to earnings ratio of 30.51. Meaning, the purchaser of the share is investing $30.51 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.99%.
Volume
Today’s last reported volume for Vertex Pharmaceuticals is 766247 which is 49.08% below its average volume of 1505060.
Sales Growth
Vertex Pharmaceuticals’s sales growth is 10.1% for the ongoing quarter and 6.3% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Vertex Pharmaceuticals’s EBITDA is 10.27.
Moving Average
Vertex Pharmaceuticals’s worth is under its 50-day moving average of $423.13 and way above its 200-day moving average of $370.34.
6. HealthStream (HSTM)
5.3% sales growth and 4.51% return on equity
HealthStream, Inc. provides Software-as-a-Service (SaaS) based applications for healthcare organizations in the United States. The company's solutions help healthcare organizations in meeting their ongoing clinical development, talent management, training, education, assessment, competency management, safety and compliance, and scheduling, as well as provider credentialing, privileging, and enrollment needs. It offers hStream, a technology platform that powers a range of healthcare workforce solutions. The company provides its solutions to customers across a range of entities within the healthcare industry, including private, not-for-profit, and government entities, as well as pharmaceutical and medical device companies through its direct sales teams. The company was incorporated in 1990 and is headquartered in Nashville, Tennessee.
Earnings Per Share
As for profitability, HealthStream has a trailing twelve months EPS of $0.5.
PE Ratio
HealthStream has a trailing twelve months price to earnings ratio of 52.98. Meaning, the purchaser of the share is investing $52.98 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.51%.
